230962-34-2

Upstream product

• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 230962-33-1 5-(3-methyl-4-phenylphenyl)pentanoyl chloride 
• 98-80-6 phenylboronic acid 
• 101711-90-4 (S)-4-benzyl-2-oxazolidinone lithium salt 
• 230962-36-4 5-(3-methyl-4-phenylphenyl)-5-oxopentanoic acid 
• 230962-32-0 5-(3-methyl-4-phenylphenyl)pentanoic acid 
• 116632-39-4 2-methyl-4-bromoiodobenzene 
• 5002-26-6 3-methyl-4-phenylbromobenzene 
• 108-55-4 glutaric anhydride, 

Downstream Products

• 230961-47-4 (2R)-N₁-[(1S)-2,2-dimethyl-1-({[(1S)-2-methoxy-1-phenylethyl]amino}carbonyl)propyl]-2-{3-(3-methyl-4-phenylphenyl)propyl}-(N₄-3-propenyloxy)butanediamide 
• 230961-86-1 tert-butyl (3R)-3-({[(1S)-2,2-dimethyl-1-({[(1S)-2-methoxy-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)-6-(3-methyl-4-phenylphenyl)hexanoate 
• 230961-21-4 UK-370106 
• 230962-37-5 (R)-2-[2-(tert-butoxy)-2-oxoethyl]-5-(2-methyl-1,1'-biphenyl-4-yl)-pentanoic acid 
• 230962-35-3 tert-butyl (3R)-3-[(4-(S)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl)carbonyl]-6-(3-methyl-4-phenylphenyl)hexanoate 

Relevant academic research and scientific papers

A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers

The pathology of chronic dermal ulcers is characterized by excessive proteolytic activity which degrades extracellular matrix (required for cell migration) and growth factors and their receptors. The overexpression of MMP-3 (stromelysin-1) and MMP-13 (col

Matrix metalloprotease inhibitors

Compounds of formula (I): or pharmaceutically acceptable salts thereof, or solvates of either entity, wherein the substituents have the values described herein, are useful as matrix metalloprotease (MMP) inhibitors